Santhera Publishes Annual Report 2022
Ad hoc announcement pursuant to Art. 53 LR Pratteln, Switzerland, May 31, 2023 – Santhera Pharmaceuticals…
Ad hoc announcement pursuant to Art. 53 LR Pratteln, Switzerland, May 31, 2023 – Santhera Pharmaceuticals…
Ad hoc announcement pursuant to Art. 53 LR Pratteln, Switzerland, May 31, 2023 – Santhera Pharmaceuticals…
SOLANA BEACH, Calif. and REDWOOD CITY, Calif., May 31, 2023 (GLOBE NEWSWIRE) — eFFECTOR Therapeutics,…
SOLANA BEACH, Calif. and REDWOOD CITY, Calif., May 31, 2023 (GLOBE NEWSWIRE) — eFFECTOR Therapeutics,…
MISSISSAUGA, Ontario, May 31, 2023 (GLOBE NEWSWIRE) — BioSyent Inc. (“BioSyent”, “the Company”, TSX Venture:…
MISSISSAUGA, Ontario, May 31, 2023 (GLOBE NEWSWIRE) — BioSyent Inc. (“BioSyent”, “the Company”, TSX Venture:…
Up to an Additional $46.2 Million Available Through Warrant Exercise Led by Novalis LifeSciences LLC…
Up to an Additional $46.2 Million Available Through Warrant Exercise Led by Novalis LifeSciences LLC…
SAN DIEGO, May 31, 2023 (GLOBE NEWSWIRE) — Oncternal Therapeutics, Inc. (Nasdaq: ONCT), a clinical-stage…
SAN DIEGO, May 31, 2023 (GLOBE NEWSWIRE) — Oncternal Therapeutics, Inc. (Nasdaq: ONCT), a clinical-stage…
BOULDER, Colo., May 31, 2023 (GLOBE NEWSWIRE) — Enliven Therapeutics, Inc. (Enliven) (Nasdaq: ELVN), a…
BOULDER, Colo., May 31, 2023 (GLOBE NEWSWIRE) — Enliven Therapeutics, Inc. (Enliven) (Nasdaq: ELVN), a…
Plans to Exit Existing U.S. hemp-derived CBD Operations Intends to Launch Lord Jones® Brand in…
Plans to Exit Existing U.S. hemp-derived CBD Operations Intends to Launch Lord Jones® Brand in…
NEW YORK, May 31, 2023 (GLOBE NEWSWIRE) — Cellectis (the “Company”) (Euronext Growth: ALCLS –…
NEW YORK, May 31, 2023 (GLOBE NEWSWIRE) — Cellectis (the “Company”) (Euronext Growth: ALCLS –…
HB-200 in combination with pembrolizumab doubled the objective response rate of 1st-line pembrolizumab for patients…
HB-200 in combination with pembrolizumab doubled the objective response rate of 1st-line pembrolizumab for patients…
SAN FRANCISCO and SHANGHAI, May 31, 2023 (GLOBE NEWSWIRE) — Structure Therapeutics Inc. (NASDAQ: GPCR),…
SAN FRANCISCO and SHANGHAI, May 31, 2023 (GLOBE NEWSWIRE) — Structure Therapeutics Inc. (NASDAQ: GPCR),…